

Date: June 25, 2026

To

The Listing Department Bombay Stock Exchange Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code: 532771	The Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G Bandra Kurla Complex Mumbai – 400051 Trading Symbol: JHS
--	--

Subject : Outcome of Meeting of Board of Directors of JHS Svendgaard Laboratories Limited (“the Company”), held on June 25, 2026.

Dear Sir/Ma’am,

In continuation of the Board Meetings held on June 04, 2024, August 03, 2024, May 17, 2025 and pursuant to the provisions of the Companies Act, 2013, applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws, the Board of Directors of JHS Svendgaard Laboratories Limited (“the Company”) at its meeting held today i.e. June 25, 2026, has, subject to approval of the shareholders of the Company, approved the variation in the utilization of proceeds raised through Preferential Issue.

The Board, in view of the evolving business requirements, manufacturing expansion plans, growth initiatives and long-term strategic objectives of the Company, approved further modification/clarification in the existing objects of utilisation of proceeds of the preferential issue, noting that the variation in utilisation of proceeds was earlier approved by the shareholders through Postal Ballot dated June 23, 2025 and that the original approval for raising funds through preferential issue was accorded by the shareholders at the Extra-Ordinary General Meeting held on July 04, 2024.

Existing Objects (as approved by shareholders on June 23, 2025):

Sr No.	Particulars	Total estimated amount to be utilized (Rs. In Lakh) *	Tentative timelines for utilization of issue proceeds from the date of receipt of funds
1	Fund the capital expenditure for acquiring equipment for manufacturing facility	599.99	By December, 2026
2	Infusion of funds in Group entities, i.e. JHS Svendgaard Retail Ventures Ltd. and/or its subsidiary, for funding the expansion plan through strategic fund infusion	1,650.00	By December, 2026
	For General Corporate Purpose*	750.00	By December, 2026
	Total	2,999.99	

(*) considering 100% conversion of Warrants into Equity Shares within the stipulated time

Note:

- All decimals have been rounded off to two decimal points.
- In terms of NSE Notice No. NSE/CML/2022/56 and BSE Notice No. 20221213-47, dated December 13, 2022, the amount specified for the above-mentioned object of issue size may deviate +/- 10% depending upon the future circumstances

Objects after the proposed amendment:

Sr No.	Particulars	Total estimated amount to be utilized (Rs. In Lakh) *	Tentative timelines for utilization of issue proceeds from the date of receipt of funds
1	Capital Expenditure and Business Expansion	1,174.99	By March 31, 2027
2	Strategic, Financial and Growth Initiatives	1,075.00	By March 31, 2027
3	For General Corporate Purpose	750.00	By March 31, 2027
Total		2,999.99	

Note:

- All decimals have been rounded off to two decimal points.
- In terms of NSE Notice No. NSE/CML/2022/56 and BSE Notice No. 20221213-47, dated December 13, 2022, the amount specified for the above-mentioned object of issue size may deviate +/- 10% depending upon the future circumstances

Details of Proposed Objects

Object No. 1 – Capital Expenditure and Business Expansion:

Funding and undertaking the capital expenditure, infrastructure, upgradation, resource sharing, manufacturing and business development initiatives of the company.

Object No. 2 – Strategic, Financial and Growth Initiatives

Undertaking strategic investments, acquisitions, expansion initiatives and restructuring activities for meeting the growth objectives of the company, whether directly and/or through investments in group companies, in form of loans, advances, inter-corporate deposits, equity or any other form of financial instruments, in compliance with applicable laws.

The proposed modification is primarily clarificatory in nature and is intended to provide greater flexibility in deployment of funds towards capital expenditure, business expansion, strategic investments, acquisitions, restructuring activities and growth initiatives, while continuing to achieve the same fundamental objectives for which the funds were originally raised.

The meeting of Board of Directors commenced at **04:11 P.M.** and concluded at **04:33 P.M.**

This is for your information and records.

Thanking You,

Yours Faithfully,

For JHS Svendgaard Laboratories Limited

Komal Jha

Company Secretary & Compliance Officer